Samsung Bioepis Named 'Leading Company of the Year' in Biosimilar Field

[Asia Economy Reporter Cho Hyun-ui] Samsung Bioepis announced on the 5th that it was selected as the winner in the 'Biosimilar Initiative' category at the Global Generic & Biosimilar Awards 2020, held virtually in the UK on the 3rd (local time).

The Global Generic & Biosimilar Awards is an annual ceremony hosted by the global media group Informa and sponsored by the multinational healthcare information service company IQVIA. The event selects companies that have achieved results in the global market over the past year in various fields such as management performance, innovation activities, social contribution, and value creation in the pharmaceutical industry.

Last month, Samsung Bioepis was named in a total of four categories, including 'Company of the Year,' from the final list of candidates chosen by a panel of 17 expert judges.

The Biosimilar Initiative category recognizes companies that have proactively worked to expand the use of biosimilars in global markets, including product approval, sales, and clinical development. Samsung Bioepis was acknowledged for its management achievements, having recorded over 210,000 biosimilar product prescriptions in Europe within eight years of its founding.

A Samsung Bioepis representative stated, "We will continue to strive to provide high-quality biopharmaceuticals to patients worldwide at reasonable prices."

This content was produced with the assistance of AI translation services.